Pfizer CentreOne Capacity Update May 2024: Cell & Gene Therapy

As an award winning global CDMO, Pfizer CentreOne uses Pfizer’s extensive scientific and technical expertise to manufacture gene and cell therapies for pharmaceutical and biotech companies like yours. With a team of over 70 experienced global Pfizer gene & cell therapy scientists and 7 years of experience working in the gene & cell therapy space, Pfizer CentreOne is well-equipped to support the development and manufacture of your advanced therapy.

Working across approximately 300,000 sq ft of world class manufacturing space in North Carolina, we have the end-to-end capability for both Drug Substance and Drug Product for Gene Therapy, as well as Viral Vector based Drug Substance Intermediate for Cell Therapy. With our extensive global network of regulatory experts and analytical and quality control engineers, we can help you overcome bottlenecks, troubleshoot fast, and help you get your innovation ready for approval in countries around the globe. All this is what makes Pfizer CentreOne your altogether different CDMO helping you to get your innovative gene and cell therapies from clinical to commercialization at speed – because for patients, time is life.

In this session from the May 2024 OPCU event, we review Pfizer CentreOne’s overall gene & cell therapy capabilities, with a focus on their ability to help meet your complex viral vector needs. We employ cutting edge technology with industry leading yield & productivity ratios for your targeted tissue, with batches ranging from 200-2000 liters. Our team of Pfizer gene & cell therapy experts have a wealth of experience, having progressed several programs from lab to market (with recent approval of Hem B in US) in development and scalable manufacturing of adeno-associated virus (AAV) vectors, across multiple serotypes, with a significant number of successes in Good Manufacturing Practice (GMP) batches and proven quality control. We are also able to extend this capability to other select viral vector platforms based on our infrastructure and expertise.